News Roundup: Albemarle Corporation (NYSE:ALB), Novartis AG (NYSE:NVS)


Albemarle Corporation (NYSE:ALB)

Albemarle Corporation (NYSE:ALB) represented a move of -1.96 percent or $-1.57 per share and closed its previous day trading session at $105.87. 2.64 Million Shares were traded in the last trading session with an Average Volume of 1.52 Million Shares. The stock currently has a Market Capitalization of 11.61 Billion.

Albemarle Corporation is a global specialty chemicals company with leading positions in lithium, bromine, refining catalysts and applied surface treatments. Albemarle powers the potential of companies in many of the world’s largest and most critical industries, from energy and communications to transportation and electronics. Working side-by-side with customers, Albemarle develops value-added, customized solutions that make them more competitive. Albemarle solutions combine the finest technology and ingredients with the knowledge and knowhow of highly experienced and talented team of operators, scientists and engineers. The company is a leading global developer, manufacturer and marketer of highly-engineered specialty chemicals that meet customer needs across a diverse range of end markets. The end markets Albemarle serve include petroleum refining, consumer electronics, energy storage, construction, automotive, lubricants, pharmaceuticals, crop protection, food safety and custom chemistry services.

The stock traded between $ 86.75 and $143.66 over 1-Year time period showing its price to sales ratio of 3.53. Albemarle Corporation (NYSE:ALB) is currently showing an INCREASING volatility over a period of 10-Days while the 20-Days Volatility showing a INCREASING trend.

Right now, the stock has a 50-Day Simple Moving Average of $6.14 and 200-Day Simple Moving Average of $7.4. Its Price to Free Cash Flow is 0 and Price to Book of 3.14.

Analyst’s recommended the stock as 2 where 1 represents Strong Buy and 5 represents Sell.

In the last Quarter, Albemarle Corporation (NYSE:ALB) reported its Actual EPS of $1.31/share. The analysts offering Earnings Estimates for the company were believing that Albemarle Corporation could bring EPS of $1.25/share. The difference between Actual EPS and Estimated EPS was 0.06 Percent. Thus showing an Earnings Surprise of 4.8 Percent.

Novartis AG (NYSE:NVS)

In the last trading session, Novartis AG (NYSE:NVS) added its value by 0.38% closing at the price of $89.24. The stock currently has market capitalization of 228.26 Billion, with average volume of 2.19 Million shares.

Beta is also a factor of measure of the relative volatility of a particular stock to the market. Currently Novartis AG (NYSE:NVS) is showing beta of 0.76. This particular value of beta suggests that Novartis AG (NYSE:NVS) has historically moved 76% for every 100% move in the benchmark, based on price level.

EPS is another important factor while making the decision of buying, selling or holding of particular share. Currently EPS for Novartis AG (NYSE:NVS) is at $5.68.

The stock currently has RSI of 60.79. RSI is considered overbought when above 70 and oversold when below 30, currently the given RSI for the stock suggests that the stock is average and it has not entered in overbought or oversold territory.

Novartis AG is committed to improving health and well-being through innovative products and services. The company aspires to capture and hold a leadership position in all of their businesses with a strong, sustainable performance based on continuous innovation. Their long-term success is founded on meeting the expectations of all our stakeholders – their customers, their people, their shareholders and the communities in which they live and work.

Novartis AG (NYSE:NVS) topped its 52-week high price of $94.19 on 01/26/18 and 52-Week Low Price of $72.30 on 06/28/18. The Stock currently has P/E (price to earnings ttm) of 15.71 and Weekly volatility of 1.19% and monthly volatility of 1.56% respectively.